The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets

Virology

Volumn 442, Issue 1, 2013, Pages 51-58

  Flynn, Jacqueline K ^a,b   Paukovics, Geza ^a   Moore, Miranda S ^a,g   Ellett, Anne ^a   Gray, Lachlan R ^a,b   Duncan, Renee ^a   Salimi, Hamid ^a,b   Jubb, Becky ^c   Westby, Mike ^c   Purcell, Damian F J ^d   Lewin, Sharon R ^a,b,e   Lee, Benhur ^f   Churchill, Melissa J ^a,b   Gorry, Paul R ^a,b,d   Roche, Michael ^a,b  

^a BURNET INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e ALFRED HOSPITAL   (Australia)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g USA   (United States)

Author keywords

Env; Gp120; HIV 1; Macrophage; Maraviroc; Resistance; T cell; Tropism

Indexed keywords

CHEMOKINE RECEPTOR CCR5; MARAVIROC; VIRUS ENVELOPE PROTEIN;

ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; EFFECTOR CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INFECTION SENSITIVITY; MACROPHAGE; MEMORY T LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; VIRAL TROPISM; VIRUS INFECTIVITY; VIRUS LOAD; VIRUS RESISTANCE; VIRUS STRAIN;

CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CYCLOHEXANES; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP120; HIV FUSION INHIBITORS; HIV-1; HUMANS; MACROPHAGES; RECEPTORS, CCR5; T-LYMPHOCYTE SUBSETS; TRIAZOLES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84878904611     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.03.026     Document Type: Article

References (46)

1. Appay V., van Lier R., Sallusto F., Roederer M. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry Part A 2008, 73:975-983.
2. Berro R., Klasse P.J., Lascano D., Flegler A., Nagashima K.A., Sanders R.W., Sakmar T.P., Hope T.J., Moore J.P. Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors. J. Virol. 2011, 85:8227-8240.
3. Berro R., Sanders R.W., Lu M., Klasse P.J., Moore J.P. Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. PLoS Pathog. 2009, 5:e1000548.
4. Bleul C.C., Wu L., Hoxie J.A., Springer T.A., Mackay C.R. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. PNAS 1997, 94:1925-1930.
5. Center R.J., Wheatley A.K., Campbell S.M., Gaeguta A.J., Peut V., Alcantara S., Siebentritt C., Kent S.J., Purcell D.F. Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens. Vaccine 2009, 27:6605-6612.
6. Chikere K., Chou T., Gorry P.R., Lee B. Affinofile profiling: how efficiency of CD4/CCR5 usage impacts the biological and pathogenic phenotype of HIV. Virology 2013, 435:81-91.
7. Chomont N., El-Far M., Ancuta P., Trautmann L., Procopio F.A., Yassine-Diab B., Boucher G., Boulassel M.R., Ghattas G., Brenchley J.M., Schacker T.W., Hill B.J., Douek D.C., Routy J.P., Haddad E.K., Sekaly R.P. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 2009, 15:893-900.
8. De Rosa S., Herzenberg L., Herzenberg L., Roederer M. 11-color, 13-parameter flow cytometry: identification of human naive T cells by phenotype, function, and T-cell receptor diversity. Nat. Med. 2001, 7:245-248.
9. Doms R.W. Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection. Virology 2000, 276:229-237.
10. Doms R.W., Trono D. The plasma membrane as a combat zone in the HIV battlefield. Genes Dev. 2000, 14:2677-2688.
11. Dragic T., Trkola A., Thompson D.A., Cormier E.G., Kajumo F.A., Maxwell E., Lin S.W., Ying W., Smith S.O., Sakmar T.P., Moore J.P. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. PNAS 2000, 97:5639-5644.
12. Etemad-Moghadam B., Sun Y., Nicholson E.K., Fernandes M., Liou K., Gomila R., Lee J., Sodroski J. Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo. J. Virol. 2000, 74:4433-4440.
13. Gao F., Morrison S.G., Robertson D.L., Thornton C.L., Craig S., Karlsson G., Sodroski J., Morgado M., Galvao-Castro B., von Briesen H., et al. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV isolation and characterization. J. Virol. 1996, 70:1651-1667.
14. Gorry P.R., Ancuta P. Coreceptors and HIV-1 pathogenesis. Curr. HIV/AIDS Rep. 2011, 8:45-53.
15. Gorry P.R., Ellett A., Lewin S.R. Maraviroc. Kucers' The Use of Antibiotics 2010, 2869-2876. Hodder & Stoughton Ltd., London. sixth ed. L. Grayson, S. Crowe, J. McCarthy, J. Mills, J. Mouton, S.R. Norrby, D. Paterson, M. Pfaller (Eds.).
16. Gray L., Churchill M.J., Keane N., Sterjovski J., Ellett A.M., Purcell D.F., Poumbourios P., Kol C., Wang B., Saksena N.K., Wesselingh S.L., Price P., French M., Gabuzda D., Gorry P.R. Genetic and functional analysis of R5×4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5delta32 allele. J. Virol. 2006, 80:3684-3691.
17. Gray L., Roche M., Churchill M.J., Sterjovski J., Ellett A., Poumbourios P., Sheffief S., Wang B., Saksena N., Purcell D.F., Wesselingh S., Cunningham A.L., Brew B.J., Gabuzda D., Gorry P.R. Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain. J. Virol. 2009, 83:5430-5441.
18. Henrich T.J., Lewine N.R., Lee S.H., Rao S.S., Berro R., Gulick R.M., Moore J.P., Tsibris A.M., Kuritzkes D.R. Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists. Antimicrob. Agents Chemother. 2012, 56:1931-1935.
19. Johnston S.H., Lobriz M.A., Nguyen S., Lassen K., Delair S., Posta F., Bryson Y.J., Arts E.J., Chou T., Lee B. A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains. J. Virol. 2009, 83:11016-11026.
20. Jubb, B., Buttler, S., Craig, C., Westby, M., 2011. Maraviroc-resistant viruses continue to use the extracellular loop and N-terminal regions of CCR5 for cell entry. In: Program and Abstracts of the 18th Conference on Retroviruses and Opportunistic Infections, Boston, February 27-March 2. Poster P590.
21. Lee B., Sharron M., Blanpain C., Doranz B.J., Vakili J., Setoh P., Berg E., Liu G., Guy H.R., Durell S.R., Parmentier M., Chang C.N., Price K., Tsang M., Doms R.W. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J. Biol. Chem. 1999, 274:9617-9626.
22. Lee B., Sharron M., Montaner L.J., Weissman D., Doms R.W. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. PNAS 1999, 96:5215-5220.
23. Maeda K., Das D., Yin P.D., Tsuchiya K., Ogata-Aoki H., Nakata H., Norman R.B., Hackney L.A., Takaoka Y., Mitsuya H. Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights into the mechanism of allosteric inhibition. J. Mol. Biol. 2008, 381:956-974.
24. Mori, J., Lewis, M., Simpson, P., Whitcomb, J., Perros, M., van der Ryst, E., Westby, M., 2008. Characterization of Maraviroc Resistance in Patients Failing Treatment with CCR5-tropic Virus in MOTIVATE 1 and MOTIVATE 2 (24 week analysis). Program and Abstracts of the Sixth European Drug Resistance Workshop, Budapest, March 26-28. Poster 51.
25. Ogert R.A., Ba L., Hou Y., Buontempo C., Qiu P., Duca J., Murgolo N., Buontempo P., Ralston R., Howe J.A. Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc. J. Virol. 2009, 83:12151-12163.
26. Ogert R.A., Hou Y., Ba L., Wojcik L., Qiu P., Murgolo N., Duca J., Dunkle L.M., Ralston R., Howe J.A. Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5. Virology 2010, 400:145-155.
27. Okoye A., Meier-Schellersheim M., Brenchley J.M., Hagen S.I., Walker J.M., Rohankhedkar M., Lum R., Edgar J.B., Planer S.I., Legasse A., Sylwester A.W., Piatak M., Lisfson J.J.D., Maino V.C., Sodora D.L., Douck D.C., Axthelm M.K., Grossman Z., Picker L.J. Progressive CD4+ central memory T cell decline results in CD4+ effector memory insufficiency and overt disease in chronic SIV infection. J. Exp. Med. 2007, 204:2171-2185.
28. Pfaff J.M., Wilen C.B., Harrison J.E., Demarest J.F., Lee B., Doms R.W., Tilton J.C. HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells. J. Virol. 2010, 84:6505-6514.
29. Pfizer Inc Maraviroc Tablets NDA 22-128: Antiviral Drugs Advisory Committee (AVDAC) Briefing Document 2007, Pfizer Inc, New York, NY.
30. Platt E.J., Wehrly K., Kuhmann S.E., Chesebro B., Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 1998, 72:2855-2864.
31. Riou C., Yassine-Diab B., Van grevenynghe J., Somogyi R., Greller L.D., Gagnon D., Gimmig S., Wilkinson P., Shi Y., Cameron M.J., Campos-Gonzalez R., Balderas R.S., Kelvin D., Sekaly R.P., Haddad E.K. Convergence of TCR and cytokine signaling leads to FOXO3a phosphorylation and drives the survival of CD4+ central memory T cells. J. Exp. Med. 2007, 204:79-91.
32. Roche M., Jakobsen M.R., Ellett A., Salimiseyedabad H., Jubb B., Westby M., Lee B., Lewin S.R., Churchill M.J., Gorry P.R. HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry. Retrovirology 2011, 8:89.
33. Roche M., Jakobsen M.R., Sterjovski J., Ellett A., Posta F., Lee B., Jubb B., Westby M., Lewin S.R., Ramsland P.A., Churchill M.J., Gorry P.R. HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less efficient mechanism of gp120-CCR5 engagement that attenuates macrophage-tropism. J. Virol. 2011, 85:4330-4342.
34. Roche, M., Salimi, H., Duncan, R., Wilkinson, B., Chikere, K., Moore, M.S., Webb, N., Zappi, H., Sterjovski, J., Flynn, J., Ellett, A., Gray, L.R., Lee, B., Jubb, B., Westby, M., Ramsland, P.A., Lewin, S.R., Payne, R., Churchill, M.J., Gorry, P.R., 2013. A common mechanism of clinical HIV-1 resistance to Maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations. Retrovirology 10, 43.
35. Salimi H., Roche M., Webb N., Gray L.R., Chikere K., Sterjovski J., Ellett A., Wesselingh S.L., Ramsland P.A., Lee B., Churchill M., Gorry P.R. Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5. J. Leukoc. Biol. 2013, 93:113-126.
36. Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712.
37. Seibert C., Ying W., Gavrilov S., Tsamis F., Kuhmann S.E., Palani A., Tagat J.R., Clader J.W., McCombie S.W., Baroudy B.M., Smith S.O., Dragic T., Moore J.P., Sakmar T.P. Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology 2006, 349:41-54.
38. Shimizu N., Tanaka A., Oue A., Mori T., Ohtsuki T., Apichartpiyakul C., Uchiumi H., Nojima Y., Hoshino H. Broad usage spectrum of G protein-coupled receptors as coreceptors by primary isolates of HIV. AIDS 2009, 23:761-769.
39. Sterjovski J., Churchill M.J., Ellett A., Gray L.R., Roche M.J., Dunfee R.L., Purcell D.F., Saksena N., Wang B., Sonza S., Wesselingh S.L., Karlsson I., Fenyo E.M., Gabuzda D., Cunningham A.L., Gorry P.R. Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. Retrovirology 2007, 4:89.
40. Tilton J.C., Doms R.W. Entry inhibitors in the treatment of HIV-1 infection. Antiviral Res. 2010, 85:91-100.
41. Tilton J.C., Wilen C.B., Didigu C.A., Sinha R., Harrison J.E., Agrawal-Gamse C., Henning E.A., Bushman F.D., Martin J.N., Deeks S.G., Doms R.W. A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J. Virol. 2010, 84:10863-10876.
42. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., Saag M.S., Wu X., Shaw G.M., Kappes J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 2002, 46:1896-1905.
43. Westby M., Lewis M., Whitcomb J., Youle M., Pozniak A.L., James I.T., Jenkins T.M., Perros M., van der Ryst E. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J. Virol. 2006, 80:4909-4920.
44. Westby M., Smith-Burchnell C., Mori J., Lewis M., Mosley M., Stockdale M., Dorr P., Ciaramella G., Perros M. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 2007, 81:2359-2371.
45. Yang X., Wyatt R., Sodroski J. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J. Virol. 2001, 75:1165-1171.
46. Yap S.H., Sheen C.W., Fahey J., Zanin M., Tyssen D., Lima V.D., Wynhoven B., Kuiper M., Sluis-Cremer N., Harrigan P.R., Tachedjian G. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med. 2007, 4:e335.